… anti-inflammatory therapies. PLGA-NPs also have the following advantages as a drug carrier:
1) PLGA has been used in the clinical settings for over forty years44) and there are limited …

… For whom then should we initiate anti-inflammatory therapy today? A good place to start
would be to consider low-dose colchicine among individuals with known atherosclerosis who …

… management only. FDG PET/CT was performed at baseline and again at 3 months after
initiation of anti-inflammatory therapy. … atherosclerosis [20]. The study group had had no statin …

… therapeutic development targeting both lipid and inflammatory factors implicated in the
pathogenesis of atherosclerosis. … evidence that use of anti-inflammatory agents have the potential …

… use of anti-inflammatory drugs can be minimized through targeted delivery of anti-inflammatory
drugs to the atherosclerotic plaque, defining the window of opportunity for treatment and …

… adjuvant use of the anti-inflammatory drugs colchicine, … therapy, but methotrexate did not.
Colchicine was cheaper than canakinumab, and it is the preferred anti-inflammatory treatment …

… atherosclerotic plaque progression. This review summarizes the rationale for personalized
anti-inflammatory therapy… the course of atherosclerosis with anti-inflammatory drugs. With …

… of new anti-inflammatory agents to manage atherosclerotic … for the development of new
therapeutic strategies in this field. … of emerging anti-inflammatory therapeutic strategies aimed …

… manifestations of atherosclerosis in recent clinical trials has led to heightened interest in
anti-inflammatory therapies. In this review, we briefly highlight some key anti-inflammatory and …

… switch in macrophages toward an anti-inflammatory phenotype [45]. A differential acetylation
pattern was also observed in VSMCs in coronary atherosclerotic lesions, which was further …